Cibc World Market Inc. Acquires 8,996 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)

Cibc World Market Inc. lifted its holdings in Editas Medicine, Inc. (NASDAQ:EDITGet Rating) by 26.1% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,485 shares of the company’s stock after acquiring an additional 8,996 shares during the period. Cibc World Market Inc.’s holdings in Editas Medicine were worth $514,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in EDIT. SG Americas Securities LLC bought a new position in shares of Editas Medicine in the first quarter worth about $721,000. Envestnet Asset Management Inc. boosted its stake in shares of Editas Medicine by 35.6% in the first quarter. Envestnet Asset Management Inc. now owns 24,061 shares of the company’s stock worth $458,000 after acquiring an additional 6,314 shares during the period. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Editas Medicine by 56.8% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 6,778 shares of the company’s stock worth $129,000 after acquiring an additional 2,455 shares during the period. HCR Wealth Advisors boosted its stake in shares of Editas Medicine by 6.3% in the first quarter. HCR Wealth Advisors now owns 21,000 shares of the company’s stock worth $399,000 after acquiring an additional 1,250 shares during the period. Finally, RMB Capital Management LLC boosted its stake in shares of Editas Medicine by 37.0% in the first quarter. RMB Capital Management LLC now owns 84,015 shares of the company’s stock worth $1,598,000 after acquiring an additional 22,688 shares during the period. Institutional investors own 68.77% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on EDIT shares. SVB Leerink dropped their price target on Editas Medicine from $14.00 to $7.00 and set a “market perform” rating for the company in a research note on Thursday, November 17th. Evercore ISI lowered their price objective on Editas Medicine to $8.00 in a research note on Monday. Oppenheimer lowered Editas Medicine from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $28.00 to $12.00 in a research note on Thursday, November 17th. Robert W. Baird lowered their price objective on Editas Medicine from $25.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday, November 18th. Finally, Chardan Capital reduced their price target on Editas Medicine from $43.00 to $35.00 and set a “buy” rating on the stock in a report on Thursday, November 17th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $15.83.

Editas Medicine Stock Up 1.8 %

EDIT opened at $10.46 on Wednesday. The stock’s fifty day moving average is $12.37 and its two-hundred day moving average is $13.47. The company has a market capitalization of $719.26 million, a P/E ratio of -3.56 and a beta of 1.96. Editas Medicine, Inc. has a 52 week low of $9.59 and a 52 week high of $34.27.

Editas Medicine (NASDAQ:EDITGet Rating) last released its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.06. The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $5.86 million. Editas Medicine had a negative return on equity of 41.33% and a negative net margin of 784.32%. Equities analysts anticipate that Editas Medicine, Inc. will post -3.23 earnings per share for the current year.

Editas Medicine Company Profile

(Get Rating)

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.

Featured Stories

Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine, Inc. (NASDAQ:EDITGet Rating).

Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.